Annals of the Russian academy of medical sciences

SCImago Journal & Country Rank
SciteSore by SCOPUS

Bimonthly peer-review medical (miscellaneous) journal

The journal "Vestnik Rossiiskoi akademii medetsinskikh nauk" = "Annals of the Russian Academy of Medical Sciences" is the authoritative scientific issue, it is published since 1946.

Editor-in-Chief

Vladimir I. Starodubov
MD, Doctor of Science (Medicine), Professor
ORCID iD: 0000-0002-3625-4278

Publisher

"Paediatrician" Publishers LLC
WEB: https://www.spr-journal.ru/ 

About

The journal releases regular articles, completed original clinical and experimental studies results in all spheres of medicine, and review articles on the most crucial problems of medical science and healthcare.

The main aims of the journal are the following:

  • to team up scientists and practitioners;
  • to draw attention to the most relevant, promising and interesting topics of medicine;
  • to build up and to develop the most promising directions in scientific field;
  • to provide relevant information on scientific research and new achievements;
  • to maintain the experience and ideas exchange between scientists from various regions.

The journal is included in the List of leading scientific journals and publications of the Higher Attestation Commission, where the main results of scientific papers for Candidate and Doctor of medicine should be published.

The journal is indexed in Ulrich's International Periodicals Directory, Scopus, Embase, EBSCO, MedArt, Russian Science Citation Index (Web of Science).

SJR (SCImago Journal Rank) (2020): 0.122
CiteScore (CiteScore metrics) (2020): 1.0
SNIP (Source Normalized Impact per Paper) (2020): 0.271

Announcements More Announcements...

 

Crossref’s ORCID autoupdate

Posted: 26.01.2017
Submitting the article to a journal of a Crossref member publisher, please, provide your ORCID ID. Crossref suggests automatically "pushing" the article metadata to your authors’ ORCID records when you include ORCID IDs in your metadata deposits.

 

Inclusion to the list of journals that follow ICMJE Recommendations

Posted: 24.06.2016
The academic journal contacted the ICMJE and was included in the list of journals that follow the ICMJE's Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.

 

Current Issue

Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 79, No 6 (2024)

Cover Page

Full Issue

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

ONCOLOGY: CURRENT ISSUES

The set of PCR-based laboratory methods for molecular diagnostics in oncology
Dribnokhodova O.P., Mironov K.O., Pozdysheva E.A., Vinokurov M.A., Korchagin V.I., Akimkin V.G.
Abstract

The development of accessible and sensitive methods for mutations analysis leading to tumor and for evaluation of patients’ individual genetic characteristics is essential for molecular genetic studies both in clinical and epidemiological research. The Central Research Institute of Epidemiology has developed a set of techniques for the qualitative detection of germinal mutations and single nucleotide polymorphisms, as well as for the quantification of the mutant alleles of somatic mutations using pyrosequencing and real-time PCR. The methods allow identifying the most common mutations in the Russian Federation in the BRCA1, BRCA2, NBN, and CHEK2 genes, responsible for hereditary tumor syndromes, and polymorphisms in the TTC34, MIR146A, CYP1A1, MICA, PAX8, MTHFR, HLA-DQB1, and HLA-DQA1 genes associated with an increased risk of cervical cancer, and in genes involved in drug biotransformation. Quantitative methods are designed to determine somatic mutations in the BRAF, KRAS, HRAS, NRAS, JAK2, MPL and CALR genes in the solid tumors and in hematology. The developed set of scientific and diagnostic techniques is being employed for analysis of genetic polymorphisms and mutations in Russian population. Some of the techniques are available as reagent kits and are used in practice.

Annals of the Russian academy of medical sciences. 2024;79(6):481-489
pages 481-489 views
Genetic and epigenetic predictors of tongue squamous cell carcinoma sensitivity to platinum drugs
Kit O.I., Engibaryan M.A., Gvaramiya A.K., Volkova V.L., Chertova N.A., Kutilin D.S.
Abstract

Background. Treatment of locally advanced malignant tumors of the tongue at the present stage of development of clinical oncology is a difficult task and is an important problem in oncology. The aim — to screen for genetic and epigenetic predictors of locally advanced tongue cancer sensitivity to platinum therapy. Methods. A comprehensive clinical and molecular genetic examination was carried out in 100 patients with locally advanced malignant tumors of the tongue, as well as 30 donors without oncological pathology. The study used a new method for the treatment of locally advanced squamous cell carcinoma of the tongue using 2-stage superselective embolization as a component of complex treatment. At the first stage, a screening bioinformatics analysis was carried out to form a panel of genetic loci associated with sensitivity to therapy with platinum drugs. The determination of the relative copy number and expression of these loci responsible for repair and for the proliferation regulation and apoptosis was performed by Real-Time qPCR. Results. Integration of RNA-seq datasets, copy number variation data, and relevant clinicopathological information from TCGA and GEO databases allowed us to identify 65 genetic loci associated with sensitivity to platinum therapy. These genes were validated in patient biological material. Laboratory screening showed differential expression of BRCA1, BLM, ERCC1, EXO1, RAD50, PIF1, LIG1, BCL2, ERBB2, MAGEH1, NGFRAP1, and CASP8 genes, correlating with changes in their tissue copy numbers, between groups of patients sensitive and resistant to platinum therapy. The profile of gene copy numbers of BRCA1, BLM, EXO1, RAD50, PIF1, LIG1, CASP8, MAGEH1 and NGFRAP1 was detected in the blood plasma of patients with squamous cell carcinoma of the tongue, which was differential for two groups of patients — sensitive and resistant to platinum therapy. Based on bootstrap models, the final gene panel was obtained: BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50 and BRCA1/EXO1, providing diagnostic sensitivity at the level of 95% and specificity at the level of 90% (AUC 0.98) when dividing patients into a group sensitive and resistant to platinum therapy. Conclusion. Comprehensive bioinformatics analysis of RNA sequencing data, gene copy number data, and clinical and pathological information from the TCGA and GEO databases, as well as laboratory screening of potential predictors, allowed us to obtain a panel of genes — BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50, and BRCA1/EXO1, the combination of which provides high diagnostic sensitivity and specificity in dividing patients into a group susceptible and resistant to platinum therapy.

Annals of the Russian academy of medical sciences. 2024;79(6):490-506
pages 490-506 views
Analysis of global practices in CAR-T cell production organization and an example of implementation at the Dmitry Rogachev National Medical Research Center for Pediatric Hematology, Oncology, and Immunology
Badrin E.A., Maschan M.A., Pershin D.E., Pyatigorskaya N.V.
Abstract

In oncology, there is a significant gap in access to advanced treatment methods, such as CAR-T therapy. Despite its high efficacy in treating refractory forms of cancer, CAR-T therapy often faces challenges due to high production costs and complex regulatory conditions. This article analyzes the global experience in CAR-T cell production and regulation, the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, and Immunology, and the prospects for CAR-T therapy development in Russia. The study identifies key factors for the successful implementation of this technology and develops recommendations for enhancing the regulatory framework and infrastructure. Special attention is given to organizing decentralized CAR-T cell production in medical centers, which we believe ensures quicker access to therapy and the development of local expertise. The study emphasizes the importance of refining the regulatory framework and continuing efforts to improve regulatory conditions and workforce training. The prospects for CAR-T therapy development in Russia are associated with expanding access to this innovative method, which can significantly improve patients’ quality of life and enhance the effectiveness of cancer treatment.

Annals of the Russian academy of medical sciences. 2024;79(6):507-514
pages 507-514 views

PEDIATRICS: CURRENT ISSUES

Effectiveness and safety of liraglutide in the treatment of childhood obesity
Sharshova O.G., Chubarov T.V., Peterkova V.A., Zhdanova O.A., Artyushchenko A.I.
Abstract

Childhood obesity remains one of the leading health problems. Recommendations for diet therapy and lifestyle changes are not always followed by patients and often do not lead to weight loss. The use of the drug liraglutide is promising in the treatment of childhood obesity. Aims — to evaluate the effectiveness and safety of using a glucagon-like peptide-1 analogue (liraglutide) in the treatment of obesity in children. Methods. A single-center prospective uncontrolled study of the use of liraglutide in children aged 12–18 years with constitutionally exogenous obesity for 12 months was conducted. The dynamics of BMI SDS (a reduction of 0.25 units or more), the presence or absence of obesity complications, complaints, and changes in laboratory indicators during the use of the drug were evaluated. Statistical analysis of the data was carried out with calculations of the arithmetic mean (M), standard deviation (SD), 95% confidence intervals, as well as the median and interquartile range (Me [25; 75]). Results. The study included 68 patients aged 12–18 years with obesity of varying degrees: 14 (20.6%) patients with grade II obesity, 40 (58.8%) children with grade III obesity, and 14 (20.6%) patients with morbid obesity. Comorbid conditions were present in 61 (89.7%) children. Non-alcoholic fatty liver disease (in 60.3% of children) and carbohydrate metabolism disorders (in 41.1% of cases) were more frequently registered in children with morbid obesity (p < 0.05). A reduction in BMI SDS was observed in 76.5% of patients, including 47 children who had a reduction of more than 0.25 kg/m². Three (4.4%) children maintained their weight (BMI SDS dynamics ± 0.05), and 7 (10.3%) patients increased their body mass. After 12 months of therapy, body weight decreased from 100,5 ± 19,7 to 99,2 ± 20,5 kg (р < 0,001), an average reduction of 6 kg (5,7%), and BMI SDS from 3,49 ± 0,66 to 2,82 ± 1,12 kg/m² (р < 0,001), an average reduction of 0,67 kg/m² (19.2%). The incidence of arterial hypertension decreased from 30.9 to 4.8% (p < 0.004), carbohydrate metabolism disorders from 41.1 to 19.4% (p = 0.004), dyslipidemia from 20.6 to 9.7%, and non-alcoholic fatty liver disease from 60.3 to 50%. Gastrointestinal side effects were reported by 10 (14.7%) patients during planned dose escalation, and in 5 patients (7.4%), the maximum tolerable dose was 2.4 mg. Conclusions. Liraglutide has shown good efficacy in the treatment of obesity in children — positive body weight dynamics at the end of therapy after 8–12 months was achieved in 76.5% of patients, 4.4% of children stabilized body weight. The decrease in patients’ body weight was accompanied by an improvement in metabolic parameters and a decrease in the detection of obesity complications. Gastrointestinal side effects were noted in 14.7% of patients during dose escalation and did not require discontinuation of therapy thereafter.

Annals of the Russian academy of medical sciences. 2024;79(6):515-522
pages 515-522 views
Analysis of the prevalence of disease risk factors among adolescents professionally oriented to medicine based on the results of the survey
Biryukova N.V., Khalfin R.A., Madyanova V.V.
Abstract

Background. Medical workers are called upon to be a standard in matters of health culture. This determines the need for its formation at all stages of continuous medical education, including at the stage of pre-professional specialized education. Aims — to study the prevalence of risk factors for health problems among senior school-age adolescents at the stage of pre-professional medical education by means of a survey. Methods. A one-stage descriptive survey was conducted in the 2022–2023 academic year with the participation of schoolchildren in grades 10–11, through an online survey using an original questionnaire aimed at identifying risk factors for health disorders among adolescents at the stage of pre-professional medical education. Results. The study showed the presence of at least one habit or risk factor for the development of health disorders in more than 90% of adolescents, schoolchildren professionally oriented to medicine. Adverse factors such as increased consumption of sweets, excessive addition of spices and salt to food, combination of eating and reading and overeating have the highest frequency, on average 37% of adolescents are prone to these habits. Conclusions. It is important to take into account the identified risk factors of health disorders when planning medical, social and educational activities for the formation of a health culture among adolescents at the stage of pre-professional medical education.

Annals of the Russian academy of medical sciences. 2024;79(6):523-530
pages 523-530 views
The dynamics of the incidence of mental disorders and behavioral disorders in older children: regional features in the Udmurt Republic
Starodubov V.I., Bezdetko G.I., Stupak V.S.
Abstract

Background. The problem of mental disorders and behavioral disorders around the world has existed for many years, but only in recent decades has it begun to receive more attention, as evidenced by the increasing number of studies devoted to this topic. In order to preserve and strengthen the health of the younger generation, it is necessary to constantly study the incidence of mental disorders and behavioral disorders, due to the impact of many different stress factors on them. Aims to determine the dynamics of the general and primary incidence of mental disorders and behavioral disorders associated with the use of psychoactive substances in the period from 2016 to 2022, and its prognosis in children aged 15–17 years for 2027. Methods. As a statistical source of information, data from the statistical reporting of the Central Research Institute of the Ministry of Health of the Russian Federation on general and primary morbidity, and the incidence of mental disorders and behavioral disorders associated with the use of psychoactive substances in children aged 15–17 years from 2016 to 2022 were used. Results. The general and primary incidence of mental disorders and behavioral disorders associated with the use of psychoactive substances in children aged 15–17 years in all studied regions in the period from 2016 to 2022 is characterized by a decrease. In the Udmurt Republic, the total and primary morbidity from 2016 to 2021 decreased by 27.8 and 25.4%, respectively. From 2021 to 2022, the indicators increased by 22.6 and 38.2%, respectively. According to data for 2022, the total incidence in the Udmurt Republic is 2.0 times higher than in the Russian Federation (RF), 1.9 times in the Volga Federal District (PFD), 1.1 times in the Republic of Bashkortostan, and 1.8 times in the Kirov Region. The primary incidence in the Udmurt Republic is 2.9 times higher than in the Russian Federation, 2.4 times in the Volga Federal District, 2.9 times in the Republic of Bashkortostan and 3.3 times in the Kirov Region. Conclusions. It was found that the overall incidence of mental disorders and behavioral disorders associated with the use of psychoactive substances in children aged 15-17 years in the dynamics from 2016 to 2021 in the Udmurt Republic is characterized by a downward trend of 27.8%, and from 2021 to 2022 by an upward trend of 22.6%. And the incidence rate with a diagnosis established for the first time in life in 2022, in comparison with 2016, is characterized by an upward trend of 17.2%. The forecast of the general and primary morbidity of mental disorders and behavioral disorders associated with the use of psychoactive substances in children aged 15-17 in the Udmurt Republic for 2027 is less than the indicators of 2022 — by 31.5% (682.7 per 100 thousand children of the corresponding age) and 38.1% (381.7), respectively. In general, we believe that high rates of general and newly identified morbidity of mental disorders and behavioral disorders associated with the use of psychoactive substances in the territory of the Udmurt Republic. The decrease in general and primary morbidity in all the studied regions from 2016 to 2020 and its further growth is associated with the epidemiological situation against the background of the COVID-19 pandemic, which led to a decrease in accessibility and appeal due to epidemic restrictions. High rates and an increase in the general and primary incidence of mental disorders and behavioral disorders in the territory of the Udmurt Republic since 2021 are associated with socio-environmental factors among the young population in the region. It is necessary to further scientifically substantiate their identification in order to develop preventive measures.

Annals of the Russian academy of medical sciences. 2024;79(6):531-538
pages 531-538 views

PHARMACOLOGY: CURRENT ISSUES

Antibiotic resistance is a Russia’s most important challenge: scientific and practical aspects, solutions
Starodubov V.I., Beregovykh V.V., Akimkin V.G., Kozlov R.S., Tutelyan A.V., Ugleva S.V., Stephani S., Rex J., Karaulov A.V., Sidorenko S.V., Basetti M., Priputnevich T.V., Stoma I.O., Svidzinsky A.V., Eckmann C., Tyumentsev A.I., Tyumentseva M.A., Prelovskaya A.N.
Abstract

The problem of antimicrobial resistance (AMR) has become particularly relevant in countries with developed healthcare systems and intensive agriculture over the past 20 years. According to the UN General Assembly on September 22, 2022, antimicrobial resistance (AMR) is already a global problem, causing almost 5 million deaths per year, and by 2050 the annual number of additional deaths worldwide could increase to 10 million persons per year. Currently, to counter the spread of AMR in the world, a partnership of 4 world organizations (WHO, OIE, FAO and UNEP) has been created, leaving the basis for the global concept of “One Health”, which is an integrated, unifying approach aimed at Sustainably balancing and optimizing the health of people, animals and ecosystems. In order to protect the population, the Government of the Russian Federation adopted the “Strategy for preventing the spread of antimicrobial resistance in the Russian Federation for the period until 2030”. The COVID-19 pandemic has impacted the spread of infections caused by multidrug-resistant bacteria worldwide. On the one hand, restrictions and preventive measures introduced in connection with the COVID-19 pandemic, such as reduced travel, distancing, hand hygiene, and environmental treatment, help reduce the spread of infections; on the other hand, the use of antibiotics in patients with COVID-19 is not always justified has exacerbated the public health threat posed by AMR, and as the pandemic progresses throughout the world, the importance of resistance has increased significantly. The resistance of microorganisms to antimicrobial drugs requires improving measures to prevent and limit the spread and circulation of pathogens with antimicrobial resistance, ensuring systemic monitoring of the spread of antimicrobial resistance, and studying the mechanisms of the emergence of antimicrobial resistance.

Annals of the Russian academy of medical sciences. 2024;79(6):539-550
pages 539-550 views
Methodological foundations of pharmaceutical development of cell-based preparations
Lyundup A.V., Beregovykh V.V.
Abstract

Background. The Russian Federation and the Eurasian Economic Union (EAEU) have developed regulatory and legal bases for the circulation of cellular drugs — treatment products based on human somatic cells. Cellular preparations in the Russian Federation are represented by biomedical cellular products with a separate regulatory regulation from medicines, and in the EAEU cellular preparations are classified as a separate class of biological medicines — high-tech medicines. In both regulatory and legal regulations, a pharmaceutical approach has been applied, involving the pharmaceutical development of a cellular drug, its preclinical and clinical studies and subsequent registration for the possibility of release into civil circulation. Cellular drug developers and potential investors are faced with a number of regulated technological and organizational work related to pharmaceutical development that must be performed to bring cellular drugs to market. The requirements, recommendations, concepts and approaches existing in the world are described only for “traditional” medicines and do not describe the necessary types of work in the development of cellular drugs. Aims — to develop methodological foundations for the pharmaceutical development of cellular drugs, as well as to develop a scale of readiness levels of cellular drug technology. Methods. Analysis of the regulatory and legal bases of the Russian Federation and the EAEU, as well as on the basis of the life cycle of cellular drugs, ICH recommendations for the development of pharmaceutical products, the concept of “quality planned during development” QbD. Results. A methodological model for the creation of cellular preparations is proposed, including the stages of theoretical development, laboratory development and industrial development. Based on the methodological model, a scale of readiness levels of cellular drug technology (UGT1–UGT9) was proposed. Conclusions. This article proposes a methodology for the pharmaceutical development of cellular preparations, taking into account a specialized scale of technological readiness levels.

Annals of the Russian academy of medical sciences. 2024;79(6):551-558
pages 551-558 views

ANNIVERSARIES

To the 70th anniversary of the Academician of the Russian academy of sciences Igor B. Ushakov
Zverev V.V.
Abstract

28 October 2024 turned 70 years old Igor Borisovich Ushakov — Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences, Honored Doctor of the Russian Federation, Chief Researcher of the State Research Center — Burnasyan Federal Medical Biophysical Center of Federal Biological Agency (Moscow).

Annals of the Russian academy of medical sciences. 2024;79(6):559-560
pages 559-560 views
To the 70th anniversary of Academician of the Russian Academy of Sciences Yuri V. Belov
Reshetov I.V., Usoltseva N.I.
Abstract

On September 5, 2024, Yuri Vladimirovich Belov, an outstanding scientist and the largest world-renowned specialist in the field of cardiovascular surgery, winner of the State Prize of the Russian Federation and the Prize of the Government of the Russian Federation in the field of science and technology, Honored Scientist of the Russian Federation, Academician of the Russian Academy of Sciences, turned 70 years old.

Annals of the Russian academy of medical sciences. 2024;79(6):561-562
pages 561-562 views
To the 75th anniversary of Academician of the Russian Academy of Sciences Vladimir G. Polyakov
Reshetov I.V., Usoltseva N.I.
Abstract

On September 14, 2024, an outstanding scientist in the field of pediatric oncology, Honored Healthcare Worker of the Russian Federation, head of the Department of Pediatric Oncology named after Academician L.A. Durnov, Federal State Budgetary Educational Institution of the Russian Ministry of Health, Advisor to the Director of the L.A. Durnov Research Institute of Pediatric Oncology and Hematology of the Federal State Budgetary Institution “National Medical Research Center of Oncology named after N.N. Blokhina” Ministry of Health of the Russian Federation, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences Vladimir Georgievich Polyakov.

Annals of the Russian academy of medical sciences. 2024;79(6):563-564
pages 563-564 views
To the 75th anniversary of Academician of the Russian Academy of Sciences Lyubov I. Kolesnikova
Dygai A.M., Reshetov I.V., Usoltseva N.I.
Abstract

Lyubov Ilyinichna Kolesnikova, a well-known scientist and the largest specialist in the field of pathological physiology, Honored Scientist of the Russian Federation, Academician of the Russian Academy of Sciences, celebrated her 75th birthday on December 20, 2024.

Annals of the Russian academy of medical sciences. 2024;79(6):565-566
pages 565-566 views
To the 75th anniversary of Academician of the Russian Academy of Sciences Anatoly A. Kulakov
Reshetov I.V., Usoltseva N.I.
Abstract

October 18, 2024 marked the 75th anniversary of the birth of the country’s leading scientist, talented leader and teacher in the field of implantology and maxillofacial surgery, Honored Scientist of the Russian Federation, laureate of the Government of the Russian Federation in the field of science and technology, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences Anatoly Alekseevich Kulakov.

Annals of the Russian academy of medical sciences. 2024;79(6):567-568
pages 567-568 views
To the 75th anniversary of Academician of the Russian Academy of Sciences Sergei F. Goncharov
Zverev V.V., Reshetov I.V., Usoltseva N.I.
Abstract

On October 19, 2024, Sergei Fedorovich Goncharov, the largest healthcare specialist, an outstanding scientist in the field of disaster medicine, a Russian statesman, a laureate of the Government of the Russian Federation in the field of science and technology, an Honored Scientist of the Russian Federation, an Honored Doctor of the Russian Federation, Academician of the Russian Academy of Sciences, turned 75 years old.

Annals of the Russian academy of medical sciences. 2024;79(6):569-570
pages 569-570 views